Claim OwnershipThe 'Dispatched' Podcast
Subscribed: 0Played: 0
Subscribe
© 2024 The 'Dispatched' Podcast
Description
BioPharmaDispatch - discussing the issues impacting the Australian biopharmaceutical and life sciences sectors with Paul Cross and Felicity McNeill.
105 Episodes
Reverse
Budget week is upon us. We share our experiences working on Budgets and discuss the behind-the-scenes process Governments undertake to develop their major annual set-piece announcement. Budgets have changed over the years with the increasing use of 'hidden' measures - which is why caution is required. Who should be telling who about communicating with patients?
The 2024-25 Budget is fast approaching. We discuss what to look for, where to exercise caution, and what to ignore. More examples of where informing is confused with consulting leading to the problematic implementation of reform.
The Albanese Government has committed an additional $3 billion for the new Community Pharmacy Agreement. The details are yet to come, but the statement and confirmed financial commitment reflect a Cabinet-endorsed Budget decision. Health Minister Mark Butler said he would now engage with "other stakeholders with an interest in the pharmacy sector to finalise separate arrangements". What do people think that means? We discuss that process, that the money will probably need to be found, and the...
We discuss speculation surrounding the new Community Pharmacy Agreement and why successive governments support the framework approaching its 35th year. Community pharmacies are a good partner for the government, and so is the industry, but for a very different reason. We also urge the industry to be true to its stated commitment to patients and publicly explain its concerns about the HTA review options paper.
The industry must be congratulated for firming up its criticism of the HTA Review options paper, and it should start speaking publicly about its concerns. The history and how agreements with the federal government have evolved over time. Another disappointment on newborn screening.
Nothing frustrates an advisory committee more than the word 'advisory'. Why any extended powers will be used to their full extent and not in the way many people would like.
With just nine days remaining for stakeholders to submit their feedback on the Health Technology Assessment Review options paper, patients must have access to all pertinent information.BioPharmaDispatch interviewed Medicines Australia chief executive and reference committee member Liz de Somer on 31 January. The interview was published on 1 February. Medicines Australia approved all included quotes.The association now appears reluctant to answer questions about its approach to the review's op...
The 'Swiss cheese' theory might explain why history is constantly repeating itself and why action is required to avoid the worst aspects of the proposals in the HTA Review options paper.
We are back for 2024 with no end of issues to discuss, starting with the HTA review options paper and the coincidence of many reviews and processes delivering outcomes just ahead of the May Budget.
Genomics and this week's CanForum, at which Rare Cancers Australia hosted several interesting discussions, particularly highlighting the patient experience and the federal government's desultory plan for an 'advisory committee'. Should the result of last weekend's referendum trigger a rethink by organisations that actively supported the proposed change?
A special week in review recorded in New Zealand with election candidate and former industry executive Todd Stephenson. We were lucky to join Mr Stephenson and ACT leader David Seymour on the campaign trail in Wanaka and Queenstown. We discuss the range of issues impacting the election, including the political and policy focus on Pharmac.
Two PBS 'demonstrations' in Canberra this week - different tones but the messages were basically the same. The complex period ahead for the PBS is reflected across the health portfolio. The raft of reviews launched by the Albanese Government since its election will start to land containing a raft of recommendations that could trigger fierce fights between stakeholder groups.
What are the wider implications of the negotiation for a new Community Pharmacy Agreement, to take effect on 1 March 2024, and can another secret policy process deliver for patients? Another managed release of information on the international HTA collaboration reveals an additional 'fragment' on its activities.
The 2023 IGR has reinforced the longstanding isolation of Budget investment in health and new therapeutic technologies as 'costs' that must be managed. It has also acknowledged the challenge of forecasting future spending beyond the short term. We discuss how the IGR and its focus on investment in health as a cost will frame the raft of current review processes.
We answer your questions today, with each of us producing our own list of five positive things about the PBS, but also the opportunities for reform.
New Zealand's Pharmac looks forward to sharing its model with counterparts in Australia, the UK and Canada, the parliament is considering new laws that will force one group of families into a very difficult and unfair decision that could have implications for every patient advocate, the government has released its long-awaited 'well-being index', and we answer your questions.
The secret involvement of Pharmac in the international HTA collaboration, why it has no place in any process that could impact patients anywhere in the world, and why industry and patients need to act to urgently block the 'dark arts' spread of its terrible ideas.
Parents are showing remarkable courage in sharing their personal stories of loss in an attempt to convince the Albanese government to implement a pre-election commitment. A typo means the planned diabetes tender will proceed simultaneously with the recently announced parliamentary inquiry. How? Are 60-day dispensing and other changes going the same way as other recent reforms?
Thoughts on the recent BPD annual conference and the latest on the dispute between the Albanese Government and pharmacy over the plan to increase dispensed quantities of over 300 medicines, including an interesting rumour. Readers' questions on a difficult discussion and next week's Senate Estimates hearing.
The 2023-24 Budget has revealed significant growth in the PBS in the current year. We unpack the numbers and discuss what might be driving potentially transformative growth. Health minister Mark Butler also announced reform of access arrangements for medicines for opiate dependence and nicotine e-cigarettes.
Comments
Download from Google Play
Download from App Store
United States